Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Evaluate Tear Characteristics Following Acute TrueTear™ Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Baseline Ocular Surface Disease Index© (OSDI©) score of at least 23 with no more than three responses of not applicable~* In at least one eye, a baseline Schirmer test of ≤ 10 mm/5 minutes AND a cotton swab nasal stimulation Schirmer test of at least 7 mm higher in the same eye~Exclusion Criteria:~* Chronic or recurrent epistaxis, coagulation disorders or other conditions that may increase the risk of bleeding~* History of nasal or sinus surgery~* Vascularized polyp, deviated septum or severe nasal airway obstruction at the Screening visit~* Intraocular and extraocular surgery in either eye within three months of the Screening Visit or refractive surgery within twelve months of the Screening Visit~* Cardiac demand pacemaker, implanted defibrillator, or other active implanted metallic or active implanted electronic device in the head

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TrueTear™ Intranasal then Extranasal Application (Type: EXPERIMENTAL): TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 14.
- TrueTear™ Extranasal then Intranasal Application (Type: EXPERIMENTAL): TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 14.

Based on this trial design, predict the completion outcome and termination type (if applicable).